Home › Multiple Myeloma › California
Multiple Myeloma clinical trials in California
68 studies for Multiple Myeloma are looking for participants at sites in California.
Cities in California
- Baldwin Park23 studies
- San Francisco17 studies
- Los Angeles15 studies
- Irvine14 studies
- Mountain View10 studies
- Orange9 studies
- Santa Monica8 studies
- Sacramento7 studies
- Burbank7 studies
- San Diego4 studies
- Roseville3 studies
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Beverly Hills Cancer Center, Beverly Hills
- Clovis Community Medical Center, Clovis
- Community Cancer Institute, Clovis
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06152575Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- City of Hope National Medical Center, Duarte
- City of Hope - Lennar Foundation Cancer Center, Irvine
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07555938A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Scripps Clinic Torrey Pines, La Jolla
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05137054cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- City of Hope, Duarte
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Nov 4, 2026 · NCT05366881A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Beverly Hills Cancer Center (BHCC), Beverly Hills
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- Stanford University Medical Center, Palo Alto
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07589634A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- City of Hope, Duarte
- University of California San Francisco, San Francisco
- Stanford University Medical Center, Stanford
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- University of California San Francisco, San Francisco
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 3, 2026 · NCT07149857A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- UCSF Fresno, Clovis
- City of Hope Duarte, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- City of Hope, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- University of California San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Duarte, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- USC Norris Comprehensive Cancer Center, Los Angeles
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05363111Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- UC San Diego Moores Cancer Center, La Jolla
- Stanford Cancer Institute, Stanford
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- City of Hope, Duarte
- Berenson Cancer Center, West Hollywood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- UC Davis Comprehensive Cancer Center, Sacramento
- UCLA Health, Jonsson Comprehensive Cancer Center, Santa Monica
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07280013AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Duarte
- Research Site, Irvine
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06106945A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06615479Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Berenson Cancer Center, Los Angeles
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07609940A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Southern California /ID# 272414, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06953960A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- City of Hope National Medical Center, Duarte
- City of Hope Irvine Lennar, Irvine
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 22, 2026 · NCT06052826A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Orange
- Research Site, San Francisco
- Research Site, Stanford
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT07735637A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- City of Hope National Medical Center /ID# 280273, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT07409246A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- City of Hope National Medical Center /ID# 273132, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911, Irvine
- University Of California, San Francisco /ID# 271662, San Francisco
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06892522A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Cedars-Sinai Medical Center /ID# 278238, Los Angeles
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07095452Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
- City of Hope Comprehensive Cancer Center, Duarte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07463807A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Duarte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07681596Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- UC Irvine, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Chao Family Comprehensive Cancer Center UCI, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06980480AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, La Jolla
- Research Site, Los Angeles
- Research Site, San Francisco
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Sacramento
- Research Site, Santa Monica
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Beverly Hills Cancer Center Clinical Research Advisors LLC, Beverly Hills
- UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- Valkyrie Clinical Trials, Los Angeles
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07073547A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- City of Hope - Duarte, Duarte
- City of Hope - Lennar, Irvine
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07336472A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University of California San Francisco, San Francisco
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- UCSF, San Francisco
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Sutter Auburn, Auburn
- Sutter Alta Bates, Berkeley
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
- and 19 more
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05892393Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
- University of California Davis Comprehensive Cancer Center, Sacramento
RecruitingObservational study
Ages 21 and older · All sexes · Updated Sep 14, 2026 · NCT04314752From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.